Carrier-Mediated Hepatic Uptake of Quinolone Antibiotics in the Rat

Abstract

The systemic clearance of many quinolone antibiotics is mainly via metabolism and urinary excretion; by contrast, biliary excretion is a major route of elimination for a new quinolone grepafloxacin (GPFX). Accordingly, we studied the hepatic uptake of GPFX because it is the first step in the drug’s hepatobiliary transport. The hepatic uptake of GPFX in vivo after i.v. administration was found to approach the hepatic blood flow, suggesting the existence of an effective hepatic uptake mechanism. To clarify this transport mechanism, GPFX uptake by isolated rat hepatocytes was examined and found to consist of a saturable component (Km173 μM, Vmax 6.96 nmol/min/mg) and a nonspecific diffusion component. The inhibition of GPFX uptake by ATP-depletors and a lack of effect after replacing Na+ with choline demonstrated that the uptake was an Na+-independent carrier-mediated active process. This uptake was inhibited by other quinolones and for lomefloxacin this was competitive in nature. Mutual inhibition studies were undertaken to investigate whether the transporter for GPFX might be the same as other transporters so far identified. GPFX inhibited the uptake of taurocholic acid, pravastatin (organic anion), cimetidine (organic cation) and ouabain (neutral steroid). However, GPFX uptake was not inhibited by these compounds. Confirmation that GPFX uptake is blood flow limited was obtained by extrapolation of the in vitro data based on mathematical modeling. In conclusion, the effective hepatic uptake of quinolone antibiotics are via carrier-mediated active transport, which is distinct from that involved in the transport of bile acids, organic anions, organic cations or neutral steroids.

Footnotes

  • Send reprint requests to: Dr. Yuichi Sugiyama, Faculty of Pharmaceutical Sciences, University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113, Japan.

  • Abbreviations:
    NQ
    quinolone antibiotics
    GPFX
    grepafloxacin
    SPFX
    sparfloxacin
    LFLX
    lomefloxacin
    OFLX
    ofloxacin
    CPFX
    ciprofloxacin
    ENX
    enoxacin
    TCA
    taurocholic acid
    oatp
    organic anion transporting polypeptide
    FCCP
    carbonylcyanide-p(trifluoromethoxy)phenyl-hydrazone
    DBSP
    dibromosulfophthalein
    DIDS
    4,4′-diisothiocyanatostilbene 2,2′-disulfonic acid
    PCMB
    p-chloromercuribenzoic acid
    ICG
    indocyanine green
    PAEB
    procainamide ethobromide
    TEA
    triethylmethylammonium
    HEPES
    4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid
    Km
    Michaelis-Menten constant, Vmax, maximum uptake rate
    Pdif
    nonspecific uptake clearance
    CL
    clearance
    AUC
    area under the curve
    Qh
    hepatic blood flow
    TLC
    thin-layer chromatography
    HPLC
    high performance liquid chromatography
    oatp
    organic anion transporting polypeptide
    • Received September 5, 1996.
    • Accepted March 21, 1997.
« Previous | Next Article »Table of Contents